Dibasic / Monobasic / Potassium Phosphate
Potassium Phosphates Injection is an intravenous phosphorus replacement used to treat low phosphorus levels in the blood and to support nutrition when oral or tube feeding is not possible.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 4 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Dibasic / Monobasic / Potassium Phosphate: Patient Information Guide
A plain-language walkthrough of Dibasic / Monobasic / Potassium Phosphate — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Potassium Phosphates Injection is an intravenous phosphorus replacement therapy used in adults and pediatric patients in two key situations:
- Hypophosphatemia (low phosphorus levels in the blood): Potassium Phosphates Injection is used when oral or enteral (tube) phosphorus replacement is not possible, insufficient, or contraindicated
- Parenteral nutrition support: Potassium Phosphates Injection provides phosphorus as part of complete IV nutrition for adults and pediatric patients who cannot be fed adequately by mouth or tube
⚙️How it works▾
Phosphorus is a mineral the body needs for an enormous range of essential functions. It helps build DNA and cell membranes, stores and transfers energy (through molecules like ATP), regulates acid-base balance, supports cell communication, and keeps bones properly mineralized. When phosphorus levels drop too low, these critical processes are impaired. Potassium Phosphates Injection delivers phosphorus directly into the bloodstream, making it immediately available to the tissues that need it.
💊How it's taken▾
Potassium Phosphates Injection is given intravenously — always through a vein, and always after being diluted into a larger IV fluid such as normal saline or dextrose solution. It is never given undiluted or as a rapid injection.
- It may be infused through a peripheral vein (in the arm) or a central venous catheter, depending on the concentration required
- The dose, concentration, and infusion rate are individualized based on the patient's age, clinical condition, lab values, and how much phosphorus they are getting from other sources
- Blood levels of phosphorus, potassium, calcium, and magnesium are checked before and during treatment to guide dosing
- This medication is administered and managed entirely by a healthcare team in a clinical setting
🤒Side effects — in detail▾
The most clinically significant side effects reported with intravenous Potassium Phosphates include:
- Hyperkalemia — dangerously high potassium levels, which can affect heart rhythm
- Hyperphosphatemia — too much phosphorus in the blood
- Hypocalcemia — low calcium levels, which can cause muscle spasms or seizures
- Hypomagnesemia — low magnesium levels
- Heart rhythm abnormalities, low blood pressure, or cardiac arrest (especially with improper administration)
- Shortness of breath or pulmonary embolism (clot-like deposits in the lung's blood vessels)
- Kidney injury, decreased urine output, or transition to chronic kidney disease
- Diarrhea, stomach pain, weakness, confusion, tingling, or paralysis
If you experience chest pain, trouble breathing, or abnormal heartbeat while receiving this infusion, alert your healthcare team immediately — these require urgent attention.
⚠️Warnings & precautions▾
- Serious cardiac risks with improper dosing or rate: Giving this medication undiluted, too fast, or in excessively large amounts has caused cardiac arrest, fatal arrhythmias, seizures, and death. It must be diluted and infused at the correct rate. ECG (heart) monitoring is recommended at higher infusion rates.
- Hyperkalemia (high potassium): This can cause life-threatening heart problems. Risk is highest in people with kidney disease, adrenal insufficiency, or those taking medications that also raise potassium. Total potassium from all sources must be considered.
- Hyperphosphatemia and hypocalcemia: Too much phosphorus can lower calcium to dangerous levels, potentially causing seizures, low blood pressure, organ damage, or kidney failure — especially in patients with initially high calcium.
- Pulmonary vascular precipitates: When mixed with calcium-containing fluids, deposits can form in the lungs' blood vessels, causing potentially fatal pulmonary embolism. Stop the infusion and seek evaluation if breathing problems develop.
- Aluminum toxicity: The product contains trace aluminum, which can accumulate to toxic levels in patients with kidney impairment. Preterm infants are at particular risk with prolonged use.
- Vein damage and thrombosis: Concentrated solutions can damage veins. Higher concentrations must be given through a central catheter.
🔀What it interacts with▾
Potassium Phosphates Injection can interact with other medications that raise potassium levels in the blood, increasing the risk of dangerous or even fatal hyperkalemia:
- Potassium-sparing diuretics (e.g., spironolactone) — reduce how much potassium is excreted, raising blood levels further
- ACE inhibitors (e.g., lisinopril) — can elevate potassium; combination raises hyperkalemia risk
- Angiotensin II receptor blockers (e.g., losartan) — similar potassium-raising effect as ACE inhibitors
- Digoxin — potassium changes can worsen digoxin's effects on the heart
- Tacrolimus and cyclosporine (immunosuppressants) — both raise potassium levels and increase the risk of severe hyperkalemia
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Do not use if you have high potassium (hyperkalemia), high phosphorus (hyperphosphatemia), high calcium (hypercalcemia), or significantly low calcium (hypocalcemia)
- Do not use if you have severe kidney disease (eGFR below 30 mL/min/1.73 m²) or end-stage renal disease — risk of life-threatening potassium buildup
- Use with caution if you have moderate kidney disease — start at a lower dose and monitor blood levels closely
- Older adults may have reduced kidney, liver, or heart function; careful dose selection and renal monitoring are recommended
- Preterm infants face higher aluminum toxicity risk with prolonged use due to immature kidneys
- Pregnancy: Recommended doses are not expected to harm the fetus. Phosphorus supplementation via this injection may be appropriate if oral/enteral intake is insufficient during pregnancy
- Breastfeeding: Phosphorus and potassium are naturally present in breast milk. Recommended doses are not expected to harm a breastfed infant. Discuss your individual situation with your care team
- Tell your provider about all other medications you take, especially anything that affects potassium levels
🚑If you take too much▾
Receiving too much Potassium Phosphates Injection — especially in large single doses or infused too rapidly — can cause extremely high phosphorus (hyperphosphatemia) and potassium (hyperkalemia) levels in the blood, leading to cardiac arrest, severe heart rhythm disturbances, seizures, low blood pressure, muscle paralysis, and death. High phosphorus also causes calcium levels to drop dangerously, and can lead to calcium deposits forming in tissues and kidneys, potentially causing acute kidney failure.
If overdose is suspected, the infusion should be stopped immediately and the care team will provide supportive treatment, including heart monitoring and correction of electrolyte levels in the blood.
🔬Pharmacokinetics — how your body processes it▾
Once infused, about 85% of phosphorus in the blood circulates freely, while the remaining 15% is bound to proteins. Phosphorus not taken up by body tissues is cleared almost entirely through the kidneys. The kidneys filter phosphorus from the blood, and more than 80% of that filtered phosphorus is actively reabsorbed back into the body by the kidney tubules — so the kidneys play a central role in regulating phosphorus balance.
📦How to store it▾
Store at 20° to 25°C (68° to 77°F) . of admixed solution, see Dosage and Administration 2.
📄 Written from Dibasic / Monobasic / Potassium Phosphate’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Dibasic / Monobasic / Potassium Phosphate — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is this medication and why am I receiving it? ▾
Is it safe to receive this while I'm pregnant or breastfeeding? ▾
What side effects should I watch out for while getting this infusion? ▾
I take lisinopril (an ACE inhibitor) for blood pressure — is that a problem? ▾
Why does it need to be given through an IV — why can't I just take a phosphorus supplement by mouth? ▾
I have kidney disease — is this medication safe for me? ▾
Is Dibasic / Monobasic / Potassium Phosphate available over the counter? ▾
When was Dibasic / Monobasic / Potassium Phosphate first available? ▾
Who makes Dibasic / Monobasic / Potassium Phosphate? ▾
💬 Answers drafted from Dibasic / Monobasic / Potassium Phosphate’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Dibasic / Monobasic / Potassium Phosphate comes
Dibasic / Monobasic / Potassium Phosphate is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Potassium Phosphates Injection is used to correct hypophosphatemia (low phosphorus) in adults and pediatric patients when oral or enteral (tube) replacement isn't possible or isn't enough
- Potassium Phosphates Injection is used to provide phosphorus as part of parenteral nutrition (IV nutrition) in adults and pediatric patients who cannot receive adequate nutrition by mouth or feeding tube
- Potassium Phosphates Injection must always be diluted before administration — never given undiluted or as a rapid IV push
- Potassium Phosphates Injection is infused into a central or peripheral vein; the concentration used depends on patient age and the type of venous access
- Potassium Phosphates Injection should only be given when the patient's serum potassium is below 4 mEq/dL — if potassium is higher, an alternative phosphorus source should be used
- Potassium Phosphates Injection requires monitoring of serum phosphorus, potassium, calcium, and magnesium levels throughout treatment
📊 Dibasic / Monobasic / Potassium Phosphate across the U.S. market
How Dibasic / Monobasic / Potassium Phosphate appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Dibasic / Monobasic / Potassium Phosphate is used
A general measure of how commonly Dibasic / Monobasic / Potassium Phosphate is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Dibasic / Monobasic / Potassium Phosphate is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Dibasic / Monobasic / Potassium Phosphate prescribed? Of the 1,596 medications we measure, Dibasic / Monobasic / Potassium Phosphate ranks #925 by Medicaid prescriptions — more than 42% of them.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Dibasic / Monobasic / Potassium Phosphate, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 5 of 14 listed Dibasic / Monobasic / Potassium Phosphate NDCs with Medicaid activity.
🔍 Compare Dibasic / Monobasic / Potassium Phosphate products
A representative set of FDA-listed product records for Dibasic / Monobasic / Potassium Phosphate — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| POTASSIUM PHOSPHATE, MONOBASIC 224 mg/mL; POTASSIUM PHOSPHATE, DIBASIC 236 mg/mL | Intravenous | American Regent, Inc. | ANDA | View NDC → |
| 236; 224 mg/mL; mg/mL | Intravenous | American Regent, Inc. | ANDA | View NDC → |
| POTASSIUM PHOSPHATE, MONOBASIC 224 mg/mL; POTASSIUM PHOSPHATE, DIBASIC 236 mg/mL | Intravenous | Amneal Pharmaceuticals Private Limited × 7 listings | ANDA | View NDC → |
| MONOBASIC POTASSIUM PHOSPHATE 224 mg/mL; DIBASIC POTASSIUM PHOSPHATE 236 mg/mL | Intravenous | Civica, Inc. | NDA | View NDC → |
| DIBASIC POTASSIUM PHOSPHATE 236 mg/mL; MONOBASIC POTASSIUM PHOSPHATE 224 mg/mL | Intravenous | Civica, Inc. | NDA | View NDC → |
| MONOBASIC POTASSIUM PHOSPHATE 224 mg/mL; DIBASIC POTASSIUM PHOSPHATE 236 mg/mL | Intravenous | Fresenius Kabi USA, LLC × 3 listings | NDA | View NDC → |
| 236; 224 mg/mL; mg/mL | Intravenous | Fresenius Kabi USA, LLC | UNAPPROVED DRUG OTHER | Find on DailyMed ↗ |
| 236; 224 mg/mL; mg/mL | Intravenous | Fresenius Kabi USA, LLC × 3 listings | NDA | View NDC → |
| 236; 224 mg/mL; mg/mL | Intravenous | Hospira, Inc. × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 236; 224 mg/mL; mg/mL | Intravenous | Puniska Healthcare Private Limited × 3 listings | ANDA | View NDC → |
Showing 23 of 23 products — FDA National Drug Code Directory. See every product, package size and price: browse all 23 Dibasic / Monobasic / Potassium Phosphate NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Dibasic / Monobasic / Potassium Phosphate — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Dibasic / Monobasic / Potassium Phosphate in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Dibasic / Monobasic / Potassium Phosphate went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
📦 Supply & shortage status
Whether Dibasic / Monobasic / Potassium Phosphate is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 4 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Fresenius Kabi USA, LLC is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.